LILLY DRN – Techwen

Novo Nordisk bets on new CEO to regain weight loss drug edge over Eli Lilly

Novo Nordisk bets on new CEO to regain weight loss drug edge over Eli Lilly

A view of the logo of Novo Nordisk at the company’s office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024.  Tom Little | Reuters Novo Nordisk is banking on fresh leadership to help it reclaim the crown in the booming weight loss drug market. The Danish drugmaker on Friday abruptly announced that … Read more

Trump most favored nations drug price executive order: What to know

Trump most favored nations drug price executive order: What to know

President Donald Trump, joined by National Institutes of Health (NIH) Director Jay Bhattacharya, speaks during a press conference in the Roosevelt Room of the White House on May 12, 2025, in Washington, DC. Andrew Harnik | Getty Images News | Getty Images President Donald Trump on Monday moved forward with a plan to lower U.S. … Read more

Trump signs order to boost U.S. drug manufacturing

Trump signs order to boost U.S. drug manufacturing

U.S. President Donald Trump speaks before signing executive orders in the Oval Office at the White House, in Washington, D.C., U.S., May 5, 2025. Leah Millis | Reuters President Donald Trump on Monday signed an executive order to incentivize drug manufacturing in the U.S., streamlining the path for pharmaceutical companies to build new production sites … Read more

Novo Nordisk legal win bars many compounded Wegovy, Ozempic drugs

Novo Nordisk legal win bars many compounded Wegovy, Ozempic drugs

Flags with the logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy are pictures while the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025.  Mads Claus Rasmussen | Afp | Getty Images Novo Nordisk scored a huge legal victory that … Read more

Eli Lilly weight loss pill orforglipron clears first late-stage trial

Eli Lilly weight loss pill orforglipron clears first late-stage trial

Eli Lilly on Thursday said its daily obesity pill met the company’s goals in the first of several late-stage trials, helping patients with Type 2 diabetes lower their blood sugar and body weight and showing safety comparable with popular injections on the market.  The trial results are among the pharmaceutical industry’s most closely watched studies … Read more